- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | P3 Health shares dip as TD Cowen cuts price target to $8 | 1 | Investing.com | ||
| 28.05. | P3 Health-Aktien fallen - TD Cowen Kursziel auf 8 US-Dollar senkt | 2 | Investing.com Deutsch | ||
| 16.05. | P3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025 | 1 | Seeking Alpha | ||
| 15.05. | P3 Health Partners GAAP EPS of -$6.28 beats by $1.64, revenue of $373.2M beats by $11.13M | 1 | Seeking Alpha | ||
| 14.05. | What to Expect from P3 Health Partners' Earnings | 1 | Benzinga.com | ||
| 04.04. | P3 Health Partners Announces 1-for-50 Reverse Stock Split | - | Investing.com | ||
| 04.04. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
| 01.04. | P3 Health Partners Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 28.03. | P3 Health stock neutral rating reiterated after earnings miss | 2 | Investing.com | ||
| 28.03. | P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M | 1 | Seeking Alpha | ||
| 13.02. | P3 Health Partners strebt Profitabilität bis 2025 mit Umsatz von bis zu 1,5 Milliarden US-Dollar an | 11 | Investing.com Deutsch | ||
| 13.02. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.12.24 | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 194 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
| 07.08.24 | P3 Health Partners Announces Second Quarter 2024 Results | 144 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,111 | 0,00 % | Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Sernova Biotherapeutics Inc - from First Berlin Equity Research GmbH 02.06.2025 / 13:39 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,800 | +8,40 % | Ascendiant Capital raises Atossa Genetics stock price target to $7.50 | ||
| PING AN HEALTHCARE | 0,755 | 0,00 % | PA GOODDOCTOR (01833): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | ||
| MOUNTAIN VALLEY MD | 0,012 | -16,44 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,274 | +3,01 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| VERU | 0,525 | -3,40 % | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial... ► Artikel lesen | |
| CYTOSORBENTS | 0,884 | -4,54 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 5,240 | -100,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| VOLITIONRX | 0,568 | -3,57 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
| EKSO BIONICS | 0,257 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.06.2025 | The following instruments on XETRA do have their first trading 02.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.06.2025
Aktien
1 LU0445408270 Altisource Portfolio... ► Artikel lesen | |
| IMUNON | 1,340 | +1,52 % | IMNN-001 shows promise in ovarian cancer treatment | ||
| BEYOND AIR | 0,158 | -1,86 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger Inc - 8-K, Current Report | ||
| NOVACYT | 0,552 | +0,36 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
| AROVELLA THERAPEUTICS | 0,039 | 0,00 % | XFRA E4NA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
P3 HEALTH PARTNERS INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu P3 HEALTH PARTNERS INC finden Sie auf Wallstreet Online.